Domo 'Regado': $51M to Fund REG1 Phase III in Thrombosis
Regado Biosciences Inc.'s hefty Series E round on the brink of a Phase III with its anticoagulant REG1 is one of the larger private financings of the year, and the $51 million bets mainly on an approach to clotbusting that the company hopes will get around the bleeding risks that have beset others.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST